Change in asthma control after 6 months of treatment with extrafine single-inhaler triple therapy in asthmatics: a real-world view from Germany

被引：0
|
作者：
Greulich, T. [1 ]
Akyildiz, B. [2 ]
Nachtigall, D. [3 ]
Bogoevska, V [3 ]
Gessner, C. [4 ]
机构：
[1] Univ Klinikum Marburg, Klin Innere Med, Schwerpunkt Pneumol, Marburg, Germany
[2] Chiesi GmbH, Hamburg, Germany
[3] Chiesi GmbH, Med Affairs, Hamburg, Germany
[4] Pois Leipzig Gbr DE, Praxis, Gessner & Gessner, Leipzig, Germany
来源：
PNEUMOLOGIE | 2023年 / 77卷
关键词：
D O I：
10.1055/s-0043-1760936
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
Po 151
引用
收藏
页码：S29 / S29
页数：1
相关论文
共 50 条
  • [41] Trioptimize IV: Improvement of Health-Related Quality of Life in Patients with COPD Treated with Extrafine Single Inhaler Triple Therapy in a Real-World Setting
    Gessner, C.
    Criee, C.
    Georges, G.
    Javan, S. Bahari
    Melchior, K.
    Hoevelmann, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [42] Single-inhaler triple versus dual bronchodilator therapy for GOLD group E and other exacerbating patients with COPD: real-world comparative effectiveness and safety
    Suissa, Samy
    EUROPEAN RESPIRATORY JOURNAL, 2023, 62 (03)
  • [43] TriOptimize II: The Use of Blood Eosinophil Count in the Care of Patients with COPD Prescribed Single Inhaler Therapy: A Real-World View from Germany
    Hoevelmann, R.
    Javan, Bahari S.
    Melchior, K.
    Pfeffermann, A.
    Gessner, C.
    PNEUMOLOGIE, 2020, 74 : S43 - S43
  • [44] Adherence and persistence to once-daily single-inhaler versus multiple-inhaler triple therapy among patients with chronic obstructive pulmonary disease in the USA: A real-world study
    Mannino, David
    Bogart, Michael
    Wu, Benjamin
    Germain, Guillaume
    Laliberte, Francois
    MacKnight, Sean D.
    Jung, Young
    Stiegler, Marjorie
    Duh, Mei Sheng
    RESPIRATORY MEDICINE, 2022, 197
  • [45] REDUCED HEALTH CARE RESOURCE UTILISATION AND COSTS FOLLOWING A SWITCH FROM MULTIPLE-INHALER TO ONCE-DAILY SINGLE-INHALER TRIPLE THERAPY IN COPD PATIENTS IN A REAL-WORLD PRIMARY CARE SETTING IN ENGLAND
    Rothnie, K. J.
    Wood, R. P.
    Czira, A.
    Banks, V. L.
    Cammidge, L. J.
    Massey, O. K.
    Seif, M.
    Compton, C.
    Sharma, R.
    Ismaila, A. S.
    VALUE IN HEALTH, 2022, 25 (12) : S484 - S484
  • [46] Real-World Effectiveness of Fluticasone Furoate/ Umeclidinium/Vilanterol Once-Daily Single-Inhaler Triple Therapy for Symptomatic COPD: The ELLITHE Non-Interventional Trial
    Beeh, Kai -Michael
    Scheithe, Karl
    Schmutzler, Heike
    Krueger, Saskia
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2024, 19 : 205 - 216
  • [47] Outcomes of patients with COPD switching from multiple-inhaler to once-daily single-inhaler triple therapy in a real-world primary care setting in England: a retrospective pre-post cohort study
    Rothnie, Kieran J.
    Wood, Robert P.
    Czira, Alexandrosz
    Banks, Victoria L.
    Camidge, Lucinda J.
    Massey, Olivia K., I
    Seif, Monica
    Compton, Chris
    Sharma, Raj
    Halpin, David M. G.
    Ismaila, Afisi S.
    Vogelmeier, Claus F.
    BMJ OPEN RESPIRATORY RESEARCH, 2024, 11 (01)
  • [48] Clinical characteristics, treatment patterns, disease burden, and persistence/adherence in patients with asthma initiating inhaled triple therapy: real-world evidence from Japan
    Suzuki, Takeo
    Fairburn-Beech, Jolyon
    Sato, Keiko
    Kaise, Toshihiko
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (06) : 1049 - 1057
  • [49] A real-world study to evaluate disease control based on symptoms severity in Greek patients with Benign Prostatic Hyperplasia (BPH) after 6 months of treatment under Fixed Dose Combination (FDC) with dutasteride/tamsulosin. The PROSPERITY I study
    Dimitriadis, G.
    Kalaitzis, C.
    Stamatiou, K.
    Kotsiris, D.
    Deirmentzoglou, S.
    Loutriotis, A.
    Papataxiarchou, K.
    Tsioumas, G.
    EUROPEAN UROLOGY, 2024, 85 : S1809 - S1809
  • [50] Retro-IDEAL study - results from real-world practice show that after substantial amounts of prior treatment with anti-VEGF and other therapies a single ILUVIEN (fluocinolone acetonide; FAc) implant leads to sustained improvements lasting up to 36 months.
    Augustin, Albert J.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2018, 59 (09)
12345